These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 29574588)

  • 1. Should Primary Prevention ICDs Still Be Placed in Patients with Non-ischemic Cardiomyopathy? A Review of the Evidence.
    Ganga HV; Maan A; Kevin Heist E
    Curr Cardiol Rep; 2018 Mar; 20(5):31. PubMed ID: 29574588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sudden cardiac death in nonischemic cardiomyopathy: Refining risk assessment.
    Zipse MM; Tzou WS
    J Cardiovasc Electrophysiol; 2017 Nov; 28(11):1361-1366. PubMed ID: 28670752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Implantable Cardioverter-Defibrillator Therapy in Patients With Nonischemic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Anantha Narayanan M; Vakil K; Reddy YN; Baskaran J; Deshmukh A; Benditt DG; Adabag S
    JACC Clin Electrophysiol; 2017 Sep; 3(9):962-970. PubMed ID: 29759721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implantable Cardioverter Defibrillators for Primary Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials.
    Stavrakis S; Asad Z; Reynolds D
    J Cardiovasc Electrophysiol; 2017 Jun; 28(6):659-665. PubMed ID: 28316104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implantable cardioverter defibrillators for primary prevention in patients with nonischemic cardiomyopathy: A systematic review and meta-analysis.
    Akel T; Lafferty J
    Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28129469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary prevention implantable cardioverter-defibrillator and opportunities for sudden cardiac death risk assessment in non-ischaemic cardiomyopathy.
    Pathak RK; Sanders P; Deo R
    Eur Heart J; 2018 Aug; 39(31):2859-2866. PubMed ID: 30020440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Implantation of Primary Prevention Implantable Cardioverter Defibrillators for Patients with Newly Diagnosed Severe Nonischemic Cardiomyopathy.
    Voskoboinik A; Bloom J; Taylor A; Mariani J
    Pacing Clin Electrophysiol; 2016 Sep; 39(9):992-8. PubMed ID: 27343008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis.
    Beggs SAS; Jhund PS; Jackson CE; McMurray JJV; Gardner RS
    Heart; 2018 Jan; 104(2):144-150. PubMed ID: 28986406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.
    Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M
    BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of implantable cardioverter defibrillator in non-ischemic cardiomyopathy: a systematic review and meta-analysis of prospective randomized clinical trials.
    Romero J; Chaudhary R; Garg J; Lupercio F; Shah N; Gupta R; Nazir T; Bozorgnia B; Natale A; Di Biase L
    J Interv Card Electrophysiol; 2017 Sep; 49(3):263-270. PubMed ID: 28674918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sudden cardiac death in nonischemic cardiomyopathy.
    Kadakia RS; Link MS; Dominic P; Morin DP
    Prog Cardiovasc Dis; 2019; 62(3):235-241. PubMed ID: 31075279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials.
    Desai AS; Fang JC; Maisel WH; Baughman KL
    JAMA; 2004 Dec; 292(23):2874-9. PubMed ID: 15598919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and study protocol for the BRITISH randomized trial (Using cardiovascular magnetic resonance identified scar as the benchmark risk indication tool for implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy and severe systolic heart failure).
    Flett A; Cebula A; Nicholas Z; Adam R; Ewings S; Prasad S; Cleland JG; Eminton Z; Curzen N
    Am Heart J; 2023 Dec; 266():149-158. PubMed ID: 37777041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality Effect of ICD in Primary Prevention of Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials.
    Luni FK; Singh H; Khan AR; Malik SA; Khawaja O; Riaz H; Lee W; Kabour A; Richards M; Aasbo J
    J Cardiovasc Electrophysiol; 2017 May; 28(5):538-543. PubMed ID: 28370885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials.
    Wolff G; Lin Y; Karathanos A; Brockmeyer M; Wolters S; Nowak B; Fürnkranz A; Makimoto H; Kelm M; Schulze V
    Clin Res Cardiol; 2017 Jul; 106(7):501-513. PubMed ID: 28213711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of implantable cardioverter-defibrillator in primary prevention of total mortality in non-ischaemic cardiomyopathy: results from a meta-analysis of prospective randomized clinical trials.
    Romero J; Díaz JC; Grushko M; Quispe R; Briceno D; Avendano R; Golive A; Pina I; Natale A; Garcia MJ; Jorde UP; Di Biase L
    Europace; 2018 Sep; 20(FI2):f211-f216. PubMed ID: 29161424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-Year Outcomes of Primary Prophylactic Use of Defibrillators for Ischemic and Non-Ischemic Cardiomyopathy　- Propensity Score-Matched Analysis From the Nippon Storm Study.
    Kondo Y; Noda T; Takanashi Y; Sasaki S; Sato Y; Nitta T; Aizwa Y; Ohe T; Kurita T
    Circ J; 2024 Jun; 88(7):1107-1114. PubMed ID: 38057099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary prevention implantable cardioverter defibrillator in patients with non-ischaemic cardiomyopathy: a meta-analysis of randomised controlled trials.
    Barakat AF; Saad M; Elgendy AY; Mentias A; Abuzaid A; Mahmoud AN; Elgendy IY
    BMJ Open; 2017 Jun; 7(6):e016352. PubMed ID: 28637742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implantable cardioverter-defibrillators: expanding indications and technologies.
    Goldberger Z; Lampert R
    JAMA; 2006 Feb; 295(7):809-18. PubMed ID: 16478904
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.